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Abstract
Aim The aim of this study was to evaluate the outcomes of
surgery for patients with secondary renal hyperparathyroidism
(rHPT).
Methods This is a retrospective cohort study. Our institutional
database was searched for eligible patients treated in 1995–
2014. The inclusion criterion was initial parathyroidectomy
for rHPT. Clinical and follow-up data were analyzed to esti-
mate the cure rate (primary outcome), and morbidity (second-
ary outcome).
Results The study group comprised 297 patients (154 fe-
males, age 44.5±13.7 years, follow-up 24.6±10.5 months),
including 268 (90.2 %) patients who had underwent subtotal
parathyroidectomy, and 29 (9.8 %) who had had incomplete
parathyroidectomy. Intraoperative iPTH assay was utilized in
207 (69.7%) explorations. Persistent rHPToccurred in 12/268
(4.5 %) patients after subtotal parathyroidectomy and 5/29
(17.2 %) subjects after incomplete parathyroidectomy
(p = 0.005). The patients operated on with intraoperative
iPTH assay had a higher cure rate than non-monitored indi-
viduals, 201/207 (97.1 %) vs. 79/90 (87.8 %), respectively
(p=0.001). In-hospital mortality occurred in 1/297 (0.3 %)
patient. The hungry bone syndrome occurred in 84/268
(31.3 %) patients after subtotal parathyroidectomy and 2/29
(6.9 %) subjects after incomplete parathyroidectomy
(p=0.006). Transient recurrent laryngeal nerve paresis oc-
curred in 14/594 (2.4 %) and permanent in 5/594 (0.8 %)
nerves at risk.
Conclusions Subtotal parathyroidectomy is a safe and effica-
cious treatment for patients with rHPT. Utilization of intraop-
erative iPTH assay can guide surgical exploration and im-
prove the cure rate.
Keywords Secondary renal hyperparathyroidism . Subtotal
parathyroidectomy . Intraoperative iPTH assay
Introduction
The most common consequence of chronic renal failure is
represented by abnormalities of calcium-phosphate metabo-
lism, leading to the patient developing secondary hyperpara-
thyroidism. High phosphate levels, low or normal calcium
concentration values, and vitamin D deficit play the funda-
mental role in the pathogenesis of the disease. Disturbances
of the mutual correlations of the above factors result in uncon-
trolled, diffuse proliferation of parathyroid cells (polyclonal
proliferation) in the initial stages of the disease, and subse-
quently in nodular proliferation (monoclonal proliferation) in
patients with higher stages of chronic kidney disease [1–5].
The introduction of chronic dialysis programs, administration
of vitamin D-derived, and phosphate-binding pharmaceuti-
cals, as well as medications that regulate the activity of the
calcium receptors through their continuous activation
(calcimimetic agents) have markedly improved the situation
of this group of patients. Unfortunately, as the disease persists,
the population of monoclonal cells increases, what on the one
hand leads to a progressive decrease in density of the calcium
and vitamin D receptors, and on the other—to a maintained,
stimulatory effect of phosphates on the parathyroid cells. Such
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a situation may pose an additional threat to the cardiac muscle
and the entire circulatory system [6–10]. According to the data
from the literature on the subject, between 15 % and approx-
imately 40 % of patients require dialysis therapy and its dura-
tion is often positively correlated with the insensitive to con-
servative therapy nodular (monoclonal) type of parathyroid
proliferation [11–13]. In such cases, a factor that plays a deci-
sive role in the therapeutic success is a properly planned and
executed surgical procedure, which—through interrupting au-
tonomous PTH release allows for a possibility of regulating
the level of phosphates and calcium as well as provides creates
favorable conditions for a kidney transplant [14].
Among the contemporary surgical methods employed in
secondary renal hyperparathyroidism, one should mention
the following: subtotal parathyroidectomy (sPTX), where
three glands and three fourths of the fourth are excised; total
parathyroidectomy with autotransplanation parathyroid frag-
ment of one gland to the sternocleidomastoid or brachioradial
muscle (TPTX +AT); total parathyroidectomy without
autotransplanation (TPTX); and total parathyroidectomy
without autotransplanation and with bilateral cervical thymec-
tomy (TPTX+BCT). From the viewpoint of the patient, the
most important goal of all modalities of treating hyperpara-
thyroidism, including surgical treatment, is improvement of
quality of life. Thus, the overall goal is resolution of symp-
toms of hyperparathyroidism, at the same time ensuring nor-
mal calcium and phosphorus metabolism in patients with end-
stage kidney disease. The strategy of surgical treatment should
thus strive for an appropriate balance between the extent of
parathyroidectomy, prevention of recurrent disease, and
avoidance of postoperative permanent hypoparathyroidism
[14–21].
The objective of the present paper based on the material
collected by the Department is an analysis of results achieved
in treating secondary renal hyperparathyroidism based on the
method of subtotal parathyroidectomy and employing intra-
operative iPTH monitoring, the operations having been per-
formed within the past 20 years.
Materials and methods
In our publication, we made an attempt at presenting the in-
clusion criteria of surgical treatment based on recommenda-
tions issued by The National Kidney Foundation Kidney
Disease Outcomes Quality Initiative and Kidney Disease:
Improving Global Outcomes (KDIGO). The KDOQI guide-
lines suggest: B… maintaining iPTH levels between two to
nine times the upper normal limit for patients in dialysis.
Surgery may further be indicated for patients with uncontrol-
lable renal HPT while medical treatment with phosphate
binders, calcium supplements, active vitamin D analogues
and cinacalcet expected long-term survival with severe
symptomatic renal HPT including pruritus, intractable bone
pain, advanced osteopenia/osteoporosis, calcinosis and
calciphylaxis.^ [14].
Based on a retrospective analysis of data originating from
the clinical register of parathyroid procedures performed in the
years 1995–2014, the assessment included a group of 297
patients operated on due to secondary renal hyperparathyroid-
ism in a single referral clinical center. Analyzing the above
patient’s group operated on in our center we noted the duration
of the chronic kidney disease±SD being 139.9±80.7 months
and duration of dialysis (mean±SD)—88.6±106.1 months.
The above data originated from medical records provided by
dialysis units. In turn, based on a retrospective analysis orig-
inating from the our clinical and ambulatory surgery registers,
we observed that well-documented data were within the range
of 1 month to more than 4 years and calculated the mean value
as more than 24 months. The analysis took into consideration
data derived from the medical history and physical examina-
tion of the patients, results of pre- and postoperative biochem-
ical diagnostic and imaging tests, data from surgical protocols,
out-patient follow-up records, and histology results. Clinical
characteristic of the investigated group is presented in Table 1.
The analyzed group of patients met the following criteria:
a) in all the patients, the cause of secondary hyperparathy-
roidism (SHP) was end-stage renal failure (RN),
b) all the patients were on renal dialysis in keeping with a
defined protocol, being dialyzed not less frequently than
three times per week,
c) biochemical confirmation of SHP was based on elevated
PTH concentration levels >500 pg/ml (N=12–65 pg/ml),
hyperphosphatemia (N=0.81–1.62mmol/l); the values of
calcemia (N = 2.2–2.6 mmol/l) and the Ca × Pi quo-
t i e n t > 5 . 6 mmo l 2 / l 2 (C a × P q >70 mg%)
(N<4.4 mmol2/l2),
d) resistance to conventional therapy (calcimimetics, vita-
min D and calcium preparations, medications decreasing
intestinal phosphate absorption),
e) intensified clinical symptoms (regardless of serum Ca
concentration levels), ostalgia and arthralgia, pruritus,
pathological fractures, metastatic calcifications and vas-
cular calcifications, signs of calciphylaxis.
Preoperative localization diagnostic management has in-
cluded ultrasound of the neck, which since 2003 has been
performed by the operating surgeon, regardless of the results
of ultrasonography performed elsewhere. Subtraction scintig-
raphy of the parathyroids was initially performed using the
technetium-thallium technique (99 m Tc+201 Tl scintigra-
phy), and subsequently by the technet ium-MIBI
(methoxyisobutylisonitrile) scan (sestaMIBI:99 m Tc MIBI
scintigraphy); the imaging was done outside our center prior
to referring the patient for surgical treatment. In the analyzed
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material, in all the reoperated patients, the diagnostic method
of choice was scintigraphy (sestamibiscan) combined with
another complementary imaging study based on magnetic res-
onance (NMR). The surgical technique included bilateral neck
exploration (BNE) performed by experienced surgical team
(in the Department where the authors are employed, approx-
imately 1000 thyroid operations are performed annually, in-
cluding approximately 110–130 parathyroidectomies-prima-
ry, secondary, and tertiary hyperparathyroidism). Having ex-
posed the space around the thyroid lobes, the recurrent laryn-
geal nerves were visualized and subsequently, the sites of the
most common location of all the four parathyroid glands were
meticulously explored and their size was macroscopically
assessed. The extent of the procedure included subtotal para-
thyroidectomy, beginning from excising three fourths of the
parenchyma of the smallest gland (leaving intact an approxi-
mately 100 mg fragment with the lowest spectrum of patho-
logic changes and normal blood supply) and subsequently
resecting the remaining enlarged and pathological parathyroid
glands. Thymectomies were performed in all the patients, in
whom visualization of all the glands was not possible; since
2003, they have become standard procedures performed in the
course of parathyroidectomy. In cases of concomitant thyroid
pathology, depending on the extent of nodular lesions, lobec-
tomy or total thyroidectomy was performed in a one-stage
procedure. Initially, the effectiveness of the surgical procedure
was assessed based on intraoperative histology (up to 2008).
At the end of 2002, the Department represented by the authors
introduced a fast intraoperative iPTH determination method
(STAT-IntraOperative-Intact-PTH Immunoassay; Future
Diagnostics, Wijchen, The Netherland) to be employed in
blood samples preoperatively, at 10 and 20 min after subtotal
parathyroidectomy. The criterion of procedure effectiveness
was assumed to be represented by a drop in iPTH concentra-
tion value following parathyroid excision by 60% after 10mi-
nutes and by at least 80 % after 20 min as compared to the
initial (preoperative) value. A decrease lower than the above-
mentioned percentages prompted a search for a supernumer-
ary gland or ectopic parathyroid tissue and was a prognostic
factor for a failure of surgical treatment [17]. The criterion of
persistent hyperparathyroidism was accepted as absence of
iPTH drop below 60 % of the initial value immediately after
surgery and 300 pg/ml in late follow-up, or an iPTH increase
within 6 months postoperatively in spite of initially observed
normalization. The mean hospitalization time was
4.9±2.5 days (1–18 days). Patients with significant postoper-
ative hypocalcemia required administration of calcium prepa-
rations and introducing calcium-containing dialyzate to their
renal dialysis program. The mean follow-up in the analyzed
group was 24.6 ± 10.5 months (1–50 months). Indirect
Table 1 Clinical characteristics
of 297 patients with renal HPT
qualified for operation in the
years 1995—2014
Age, mean ± SD (years) 44.5 ± 13.7
Sex ratio (M:F), number 154/143
Duration of the chronic kidney disease ± SD (month) 139.9 ± 80.7
Duration of dialysis mean ± SD (month) 88.6 ± 106.1
Weight of removed parathyroid gland per patient; mean ± SD (g) 4.53 ± 1.5
Intrathymic localization number (%) 64 (21.5)
Causes of renal HPT
Glomerular and tubular kidney disease:
a) primary: focal segmental glomerulosclerosis immunological nephropathy number (%) 203 (68.3)
b) polycystic kidney disease number (%) 27 (9.1)
c) secondary: diabetic nephropathy number (%) 12 (4.1)
Another kidney disease:
e.g.: lupus nephritis, primary and secondary amyloidosis, bilateral renal
artery stenosis number (%)
55 (18.5)
Comorbid diseases and signs:
hypertension number (%) 232 (78.1)
Cardiac diseases:
e.g.: coronary artery disease, cardiac dysrhythmia, myocardial infarcaction
number (%)
77 (25.9)
Digestive tract diseases:
e.g.: peptic ulcers, cholelithiasis number (%) 69 (23.2)
soft tissue calcification number (%) 63 (21.2)
itching of the skin, muscle weakness, ostalgia 241 (81.1)
Comorbid nodular goiter number (%) 31 (18.6)
Time of hospitalization (days) (mean ± SD) 4.9 ± 2.5
Mean follow-up (months) (mean ± SD) 24.6 ± 10.5
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laryngoscopy is performed in each patient by an ENT special-
ist on day 1 postoperatively and calcium levels were deter-
mined, assuming hypocalcemia to occur at total calcium levels
below 2.0 mmol/l. In our Department, the patients have been
divided into three groups, depending on serum calcium con-
centration values; thus, we have distinguished between pa-
tients with mild (2.0–2.19 mmol/l), moderate (1.8–
1.99 mmol/l), and severe (<1.8 mmol/l) hypocalcemia.
The statistical analysis was performed employing the
STATISTICA software (version 10, StatSoft, Poland).
Assessment of the variability of the investigated vari-
ables was performed by means of arithmetic means,
standard deviation (SD), minimum and maximum values
(min-max) , and prevalence ra tes expressed as
percentages.
An inter-group comparison of particular properties was
performed by the student’s t test for variables with normal
distribution and by the χ square test for the remaining
variables.
The significance level was assumed to be α≤0.05.
Results
In the analyzed group of 297 patients, no significant differ-
ences were noted between the number of females and males
(143 vs. 154), while the mean age was 44.5±13.7 years (16–
79 years). Themean follow-up timewas slightly above 2 years
(24.6±10.5 months). The duration of hemodialysis treatment,
although being within a fairly wide range of 2 to 20 years, was
approximately 7 years on the average (88.6±106.1 years). In
turn, the mean duration of chronic kidney disease treatment
did not exceed 12 years (139.9±80.7). The most common
cause of renal failure (81.5 %) was primary or secondary glo-
merular or tubular damage. In the remaining cases (18.5 %),
renal failure developed with other disease entities as the back-
ground, with systemic autoimmune diseases and vascular le-
sions predominating.
Among concomitant diseases, the most numerous group
included patients with arterial hypertension and diseases
involving the coronary vessels and cardiac muscle (78.1
and 25.9 %, respectively). Sixty-three patients (21.2 %)
presented with calcium deposits deposited in the soft tis-
sues, mainly in the subcutaneous tissue of the lower and
upper extremities, both in the straight fragments of the
limbs and in the joint regions. Concomitant thyroid pathol-
ogies manifested as non-toxic nodular goiter were ob-
served in 31 patients (18.6 %). The mean duration of
hospitalization was approximately 5 days (4.9±2.5). One
patient died (1/297=0.3 %) (Table 1).
In the analyzed 20-year period, 268 (90.2 %) patients were
subjected to subtotal parathyroidectomy; in the remaining
group of 29 patients (9.8 %), the procedure was incomplete.
In both the analyzed groups, the mean preoperative concen-
tration values of PTH (sPTX group 1531.4 ± 647.8 versus
incomp PTX group 1588.1 ± 609.7), calcium (sPTX group
2.56±0.05 versus incomp PTX group 2.58±0.02), and phos-
phates (sPTX group 2.41±0.52 versus incomp PTX group
2.38±0.38) did not differ.
Persistent hyperparathyroidism was noted in 12/268 (4.5 %)
patients after subtotal resection of the glands and in 5/29
(17.2 %) patients in the second analyzed group. The values
were statistically significant (p=0.005). Intraoperative iPTH
monitoring allowed for achieving a higher percentage of per-
manent cures in late follow-up in the group of patients with vs.
without intraoperative iPTH monitoring (IOPTH group 201/
207–97.1 % versus without iPTH group 79/90–87.8 %)
(p=0.001). The values were statistically significant.
In the group of patients after subtotal parathyroidectomy, a
significant decrease was noted in phosphate levels 6 months
after surgery as compared to the group of patients with incom-
plete parathyroid resection (sPTX group 1.48±0.51 versus
incomp PTX group 2.32±0.41; p<0.001).
A similar relationship was also observed with respect to the
mean PTH concentration values in the two analyzed groups
6 months after the surgery (sPTX group 122.9±182.2 versus
incomp PTX group 344.5 ± 208.3; p<0.001). Despite oral
calcium and vitamin D supplementation (Calperos 1 g 3×2
tablets/day; Alphadiol 1 caps. μg/day), 84 patients after sub-
total parathyroidectomy-manifested symptoms of intensified
hypocalcemia and hypophosphatemia, what allowed for diag-
nosing the hungry bone syndrome. These patients required
intravenous calcium administration and dialysis treatment
with calcium-containing dialyzate. The above association
was reflected in the statistically significant difference
(p=0.006) in the manifestation of symptoms of the hungry
bone syndrome between the two analyzed groups (sPTX
group 31.3 % (84/268) versus incomplete PTX group 6.9 %
(2/29). There was noted difference in postoperative transient
recurrent laryngeal nerve paresis. Transient unilateral paresis
of the recurrent laryngeal nerve was noted in 6/58 (10.3 %;
p<0.001) patients in incomplete PTX group, while permanent
paresis was seen in 3/58 (5.2 %) cases in the same group (in
relation to 594 nerves at risk) (Table 2).
In 17 patients with persistent hyperparathyroidism, elevat-
ed PTH values were noted at follow-up 6 months postopera-
tively (after 6 months 567.3±234.2 pg/ml). Nevertheless, on-
ly eight patients from this group showed the mean PTH values
amounting to 1296.6±304.6 pg/ml 18 months postoperative-
ly; p<0.001 (Table 3). The patients needed reoperation. The
cause of persistent hyperparathyroidemia in the group with
intraoperative PTH concentration monitoring was the pres-
ence of three supernumerary parathyroid glands, while in the
group without PTH determinations—the presence of one su-
pernumerary parathyroid gland and four ectopically situated
parathyroids. The precise location of the reoperated
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parathyroid glands and PTH levels is presented in Fig. 1a, b
and Fig. 2.
Discussion
A consequence of renal failure is the patient developing sec-
ondary hyperparathyroidism. As it follows from the reports of
the European Society of Dialysis and Transplantation, the du-
ration of dialysis treatment is a factor affecting qualification of
patients to parathyroidectomy. A decision to choose a treat-
ment modality (surgical/conservative) always requires a dis-
cussion among members of an interdisciplinary team, most
commonly including nephrologists, surgeons, anesthesiolo-
gists or cardiologists. As we know, the introduction of
calcimimetics has resulted in a significant decrease in the
number of patients referred for surgical treatment; neverthe-
less, in keeping with data from the world literature, it is as-
sumed that each year, approximately 1–2 % of patients with
renal hyperparathyroidism require parathyroidectomies [10,
20–23]. In the presently analyzed material, the mean age of
the patients, the duration of renal failure, and the mean dura-
tion of dialysis treatment did not fundamentally differ from
data reported in the literature on the subject. The principal
cause of the developing renal failure is believed to be repre-
sented by primary diseases of the glomeruli and tubules, as
well as autoimmune disorders, which lead to secondary de-
struction of renal parenchyma. In the present material, in
86.8 % patients the lesions developed in the presence of the
above underlying diseases and only in less than 5 % (4.1 %),
diabetic nephropathy was responsible for renal failure. The
above data approximate findings from the literature; where
at present, diabetic nephropathy accounts for a low percentage
of causes of CRF; what is an evidence of progress having
occurred over the years in proper management of diabetic
patients [11–13, 20, 21].
Progressive kidney damage leading to destruction of neph-
ron function is associated with abnormal functioning of the
feedback axis associated with calcium and phosphate ions.
Nevertheless, the key role is ascribed here to phosphates, the
Table 2 Comparison of two
groups of 297 patients
undergoing subtotal PTX and
incomplete PTX surgery with
rHPT
Subtotal PTX Incomplete PTX P
Number of patients (%) 268 (90.2) 29 (9.8) NA
iPTH pg/ml (mean ± SD)
preoperatively baseline 1531.4 ± 647.8 1588.1 ± 609.7 0.651
6 months postoperatively 122.9 ± 182.2 344.5 ± 208.3 <0.001
Average serum calcium level mmol/l (mean ± SD)
preoperatively baseline 2.56 ± 0.05 2.58 ± 0.02 0.034
6 months postoperatively 2.31 ± 0.21 2.55 ± 0.01 <0.001
Average serum phosphorus level mmol/l (mean ± SD)
preoperatively baseline 2.41 ± 0.52 2.38 ± 0.38 0.763
6 months postoperatively 1.48 ± 0.51 2.32 ± 0.41 <0.001
Persistent disease, number (%) 12 (4.5) 5 (17.2) 0.005
Hungry bone syndrome, number (%) 84 (31.3) 2 (6.9) 0.006
Unilateral RLN injury, number (%)a
transient 8 (1.5) 6 (10.3) <0.001
permanent 2 (0.4) 3 (5.2) 0.003
Reference range 12–65 pg/ml, calcium total 2.2–2.6 mmol/l; phosphate 0.81–1.62 mmol/l
NA not available, iPTH parathyroid hormone
a RLN injury was calculated for nerves at risk and not for patients (there were 594 nerves at risk in all patients with
rHPT group)
Table 3 Mean iPTH serum
levels in the group patients with
unsuccessful first operation in
rHPT (persistent rHPT)
Persistent rHPT requiring
reoperation (n = 8)
Persistent rHPT without
reoperation (n= 9)
P
Time resection iPTH±SD iPTH±SD
Preoperative baseline 1563.9 ± 485.8 1397.3 ± 459.5 0.479
Follow-up
6 months after first operation 721.1 ± 239.6 413.4 ± 70.3 0.002
18 months after first operation 1296.6 ± 304.6 631.4 ± 115.28 <0.001
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level of which is regulated by well-functioning proximal renal
tubules [12, 13, 22]. Thus, concentration values of PTH and
phosphates play a decisive role in determining the intensity of
various symptoms, and the very Ca×P quotient predominant-
ly depends on their concentration values, in this way becom-
ing a significant factor implicated in skin lesions, calcifica-
tions involving the soft tissues or deposition of calcified ath-
erosclerotic plaques in the vascular walls.
Analyzing the present data in terms of the occurrence and
intensity of skin symptoms, pruritus, ostalgia (81.1 %) as well
as arterial hypertension (78.1 %) and other diseases of the
circulatory system (25.9 %), we noted that they did not differ
from the data from the literature, as the same time pointing to
the role of high serum phosphate values in patients on dialysis
treatment (Tables 1 and 2) [10].
In our Department, surgical treatment of hyperparathyroid-
ism in patients with renal failure is based on subtotal parathy-
roidectomies, in view of the fact that their advantages include
preservation of hormonal function by the parathyroid stump
with normal blood supply left in situ, creation of favorable
conditions for postoperative serum calcium monitoring, and
in case of patients awaiting a kidney transplant, taking into
consideration duration of dialysis therapy, it provides favor-
able conditions for such a procedure, preventing damaging the
transplanted kidney. The above-presented method of surgical
treatment was employed in 268/297 (90.2 %) patients. The
remaining group included individuals subjected to incomplete
resection of the glands (29/297—9.8 %). In this group, 5/29
(17.2 %) cases of persistent hyperparathyroidism were noted,
what—as compared to the number of patients presenting with
persistent hyperparathyroidism (12/268—4.5 %) following
subtotal parathyroidectomy—yielded a statistically significant
result. The above data were comparable to the findings report-
ed in the world literature on the subject [23–27]. As it follows
from the human ontogenetic development, the said variability
results from the variable origin of the superior and inferior
parathyroid buds (III and IV pharyngeal folds) and their sub-
sequent migration in the course of fetal maturation and
growth. Failures in surgical treatment of secondary hyperpara-
thyroidism are thus most commonly the result of missing a
supernumerary (e.g., fifth) or ectopically situated parathyroid
gland or an inadequate resection of the glands [20, 28, 29].
Irrespectively of the above-mentioned causes, such patients
require treatment. Does it always has to be surgical treatment and
is there a method allowing for a better assessment of prognostic
factors predicting a success of operative treatment? While ana-
lyzing the period of past 20 years, the authors found out that the
effectiveness and successfulness of the surgical procedure were
affected by the method of prompt intraoperative iPTH monitor-
ing introduced in the Department at the end of 2002. The crite-
rion of operation effectiveness was a 60 % decrease in iPTH
concentration value after 10 min and at least an 80 % decrease
20 min postparathyroidectomy as compared to the initial
(preoperative) value. A drop lower than the above-mentioned
iPTH concentration values favored a search for supranumerary
or ectopic parathyroid tissue and was a prognostic factor of an
operative failure—a higher permanent cure rate as compared to
patients without intraoperative iPTH monitoring (IOPTH group
201/207 (97.1 %) versus without iPTH group 79/90 (87.8 %),
(p=0.001)). The values were statistically significant [17, 18].
Special attention should be paid to a skilful interpretation of
results based on the knowledge of the kinetics of PTH level
decrease in a unit of time and the resultant implications
a
b
Fig. 1 aLocalization of the resected ectopic parathyroid gland in patients
with rHPT (anterior-posterior view). Localization of ectopic and
supernumerary parathyroid glands: mediastinal outside thymus,
retroesophageal space, intrathymic, intrathyroid, near hyoid bone, and
near carotid sheath. b Localization of the resected ectopic parathyroid
gland in patients with rHPT (lateral view). Localization of ectopic
gland: retroesophageal space
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addressing the occurrence of both falsely positive and falsely
negative results. Looking back at the past 20 years of parathy-
roid surgery in our center, we do realize the important role of
iPTH monitoring and of accuracy and ability to interpret the
results and therefore make therapeutic decisions in severely ill
patients with renal hyperparathyroidism. False positive results
defined as a significant intraoperative iPTH decrease in a pa-
tient with persistent postoperative hyperparathyroidism occur
on the average in 3–5 % of cases. In our Department: the
criterion of surgery effectiveness is assumed to be a drop in
iPTH concentration value by 60 % after 10 min and at least by
80 % after 20 min as compared to the initial value. Such iPTH
values give a better guarantee that the result is not false positive.
A drop lower than the above-mentioned iPTH values prompts a
search for supranumerary or ectopic parathyroid tissue and is a
prognostic factor of an operative failure. Another problem is
posed by falsely negative results, defined as a non-significant
drop in iPTH level, in spite of successful parathyroidectomy
having been performed. The incidence of such results is lower
as compared to false positive results and as a rule does not
exceed 2 %. Such a result is affected by knowledge of the
iPTH half-life (generally approximately 4 min on the average)
and a pronounced increase of iPTH level during parathyroids
preparation prior to their resection. Employment of the afore-
mentioned protocol by the authors, i.e., collection of at least
two blood samples for iPTH determinations at 10 and 20 min
following parathyroids resection to a great extent eliminated the
possibility of obtaining a false negative result caused by the
very variability of iPTH kinetics (the period is several times
longer than the iPTH half-life) [17]. As it has been mentioned,
in the investigated group, 17 patients demonstrated persistent
hyperparathyroidism in 5/29 (17.2 %) in the group subjected to
incomplete parathyroidectomy and in 12/268 (4.5 %) of indi-
viduals after subtotal parathyroidectomy. According to the lit-
erature, the percentage covers a relatively broad range of 5–
34 % [30–33]. The introduction of modern scintigraphic imag-
ing methods (123I/99mTc-Sestamibi SPECT/single photon
emission computed tomography/) and the use of magnetic res-
onance imaging (MRI) is of a great assistance in identification
of supernumerary or ectopic parathyroid tissue. In the analyzed
material, in all the reoperated patients, the diagnostic method of
choice was scintigraphy (sestamibiscan) combined with anoth-
er complementary imaging study based on magnetic resonance
(NMR). It should be emphasized that while analyzing various
imaging methods, one may perceive certain regularity—a larg-
er parathyroid gland means a better chance for its visualization
and by the same token for a successful surgical treatment.
Based on the above observation, one may also surmise that
the size and weight of parathyroid glands may be helpful in
their identification during surgery. In the present material, the
mean weight of the resected parathyroid glands was approxi-
mately 4.5 g [24, 34, 35].
Do all patients, however, require a reoperation? On the one
hand, finding a parathyroid gland in location diagnostics and
biochemical criteria of an operative failure is highly helpful in
making the decision to reoperate. On the other hand, some
persistent rHPT
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without reoperation
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authors are of the opinion that maintaining the hormone level
that is two–fourfold higher than the normal value affects both
the level of calcium and phosphates, what in combination with
the knowledge of progressing with disease duration time resis-
tance of bone tissue to parathormone and prevention of ady-
namic bone disease is of a paramount importance in quality of
life of surgical patients. Therefore, some authors believe that
sPTX is a better therapeutic method for dialyzed patients
awaiting a kidney transplant, since overcoming PTH autono-
my, it prevents damaging the transplanted kidney. This is also
important for another reason: as it has been observed in patients
with tertiary hyperparathyroidism, posttransplantation renal
failure manifested as a higher decrease in GFR was higher in
TPTX+AT patients as compared to patients after sPTX. In
turn, total parathyroidectomies may be more frequently
employed in patients who are not candidates for kidney trans-
plants; nevertheless, it requires exercising much caution in
postoperative management. This affects both the level of calci-
um and phosphates. Hypocalcemia and developing symptoms
of the hungry bone syndrome are not solely the result of exces-
sive incorporation of calcium to the osseous system, but also of
the postoperative drop in phosphate levels. This is why moni-
toring of postoperative calcium values is justified only as a
preventive measure of developing hypocalcemia with its un-
comfortable symptoms, but it not always defines the effective-
ness of surgical treatment. Hence, there emerges a long-term
need for monitoring both the level of PTH and phosphates in
patients subjected to parathyroidectomy. Normalization of the
above parameters provides good foundations for a renal trans-
plant, decreasing the number of early rejections [33, 36–38].
In the present material of 17 patients (5/29 incomplete PTX+
12/268 sPTX) with unsuccessful primary procedures, who man-
ifested a PTH level increase 6 and 18 months postoperatively,
reoperations were performed in eight subjects with PTH levels
being significantly higher as compared to the remaining patients
not qualified for reoperations (1296.6±304.6 versus 631.4
±115.28; <0.001) (Table 3). The analysis of causes of persistent
hyperparathyroidism demonstrated that in the group of
reoperated patients with IOPTH (3/6 in the group of 207 patients
with IOPTH), the main cause of high PTH concentration values
18 months after the primary procedure was supernumerary, ec-
topic parathyroid glands situated in the mediastinum and deep
within the thymus, while in the remaining group of patients with-
out IOPTH (5/11 of the group of 90 patients), ectopic abnormal-
ities predominated, their location being variable and involving the
neck and mediastinum (Fig. 1a and b), (Fig. 2) [10, 17–35, 39].
Although a retrospective analysis of the data demonstrates
the effectiveness of a standardized operative method
employing intraoperative PTHmonitoring, the relatively short
follow-up time in the analyzed group (24.6±10.5) limits an-
swering another question, i.e., whether renal failure affects
changes in PTH metabolism and by the same token affects
assessment of the effectiveness of surgery.
The analysis of the literature describing the results of all
types of surgical treatment employed in secondary hyperpara-
thyroidism does not provide us with unambiguous criteria of
the selection and supremacy of a single given method. The
ultimate goal is always resolution of hyperparathyroidism
symptoms at the same time providing the patients with end-
stage renal disease with a guarantee of normal calcium and
phosphorus metabolism. Some authors believe that sPTX is a
better therapeutic method for dialyzed patients awaiting a kid-
ney transplant, since, breaking the PTH autonomy, it prevents
damage to the transplanted kidney; in turn, total parathyroid-
ectomy may be more frequently employed in patients who are
not candidates to kidney transplants, but the modality requires
exercising much caution in postoperative management.
Summing up, based on numerous publications on surgical
treatment of secondary hyperparathyroidism, it should be stat-
ed that both subtotal PTX and TPTX+AT and standard cervi-
cal thymectomy represent procedures that ensure a postoper-
ative success with an acceptable and satisfactory percentage of
permanent hypoparathyroidism [27, 33, 36–38, 40–44].
Both the advocates and opponents of particular therapeutic
methods employed in secondary renal hyperparathyroidism
agree that routine IOPTH becomes of assistance in determining
the effectiveness of the operation with respect to its extent, is a
helpful criterion in reaching a decision to complete the proce-
dure, at the same time being a prognostic factor of treatment
adequacy and in a situation when there is no significant drop
in concentration values, it provides the surgeon with an oppor-
tunity to decide on further exploration of the surgical field to seek
ectopic glands [40–44].
In the opinion of the authors, the decisive factors that affect
the effectiveness of surgical treatment in rHPT is the experi-
ence of the surgeons and of the center whether treatment is
provided, accessibility of intraoperative iPTH monitoring
knowledge of mechanisms that regulate the calcium-
phosphate metabolism and follow-up duration.
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